Search - tctmd.com

Displaying 901 - 920 of 1174

Sort: Relevancy | Date

News Daily News

Las Estatinas Reducen las Amputaciones tras Intervenciones en Extremidades Inferiores

Jason Kahn

December 30, 2013

Presentation

Transport to Primary PCI vs. On-site Fibrinolysis Is Independent Predictor of Functional Status after MI

Presenter: D.M. Bilkova

December 16, 2013

News Daily News

Bivalirudin Lowers Post-PCI Bleeding Risk Across All Renal Dysfunction Categories

December 10, 2013

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Presenter: Eli Lev

December 01, 2013

News Daily News

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

Caitlin E. Cox

November 01, 2013

News Daily News

HORIZONS-AMI：使用比伐卢定减少出血仅为死亡率降低的部分原因

Caitlin E. Cox

November 01, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presenter: Bernard Chevalier

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

Presentation TCT 2013

Antithrombin Therapy (GP IIb/IIIa inhibitors) in Patients with ACS and Those Undergoing PCI

Presenter: Sripal Bangalore

October 27, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Daily News

无并发症DES患者长期使用阿司匹林与双联疗法效果相同

Jason Kahn

October 11, 2013

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

Advertisement

Las Estatinas Reducen las Amputaciones tras Intervenciones en Extremidades Inferiores

Transport to Primary PCI vs. On-site Fibrinolysis Is Independent Predictor of Functional Status after MI

Bivalirudin Lowers Post-PCI Bleeding Risk Across All Renal Dysfunction Categories

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

HORIZONS-AMI：使用比伐卢定减少出血仅为死亡率降低的部分原因

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Antithrombin Therapy (GP IIb/IIIa inhibitors) in Patients with ACS and Those Undergoing PCI

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

无并发症DES患者长期使用阿司匹林与双联疗法效果相同

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content